tiziana-logo.png
Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
24 avr. 2023 07h00 HE | Tiziana Life Sciences Ltd.
NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
tiziana-logo.png
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
20 avr. 2023 07h00 HE | Tiziana Life Sciences Ltd.
Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023Tiziana guided by FDA Type “B” meeting comments on its scheduled Q2 2023 intranasal foralumab...
tiziana-logo.png
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
18 avr. 2023 07h00 HE | Tiziana Life Sciences Ltd.
CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by SanofiMechanism of Action of Tiziana’s first-in-class, only...
tiziana-logo.png
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
13 avr. 2023 07h00 HE | Tiziana Life Sciences Ltd.
Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system an estimated $2.6 trillionThe role of activated microglia is well-established...
tiziana-logo.png
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai
10 avr. 2023 07h00 HE | Tiziana Life Sciences Ltd.
Exhibition will run from March 31st to May 21st, 2023, at Prada Rong ZhaiScientific Conference will be held on April 20th, 2023, at Prada Rong Zhai NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) --...
tiziana-logo.png
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
04 avr. 2023 10h43 HE | Tiziana Life Sciences Ltd.
Dr. Saef Izzy’s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke)Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have...
tiziana-logo.png
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
04 avr. 2023 07h00 HE | Tiziana Life Sciences Ltd.
Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemorrhagic strokeData shows behavioral outcomes improvement at one month in model of...
tiziana-logo.png
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in Sweden
31 mars 2023 07h00 HE | Tiziana Life Sciences Ltd.
Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD)Modulation of neuroinflammation may be synergistic to existing treatments in AD NEW...
tiziana-logo.png
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
28 mars 2023 07h00 HE | Tiziana Life Sciences Ltd.
First Phase 2 trial employing intranasal foralumab for treating inflammatory neurological diseaseTiziana received FDA Type C Meeting Minutes for proposed Phase 2 clinical trial in patients with...
tiziana-logo.png
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
22 mars 2023 07h00 HE | Tiziana Life Sciences Ltd.
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...